Skip to main content
Fig. 7 | BMC Medicine

Fig. 7

From: Effects of acetazolamide combined with remote ischemic preconditioning on risk of acute mountain sickness: a randomized clinical trial

Fig. 7

Decrease in PDGF-AB from baseline to pre-hypoxia in different subgroups of PDGFA SNPs. Each point in the graph represents the difference in PDGF-AB concentrations from baseline to pre-hypoxia for an individual. The asterisk (*) indicates a significant decrease of PDGF-AB from baseline to pre-hypoxia within the specific genotype group. a Decrease in PDGF-AB levels in different subgroups of PDGFA rs2070958. Individuals carrying the rs2070958 T allele (TT or TC) in both Acetazolamide and Ripc groups showed a significant decrease in PDGF-AB levels. b Decrease in PDGF-AB levels in different subgroups of PDGFA rs9690350. Individuals carrying the rs9690350 C allele (CC or CG) in Ripc group showed a significant decrease in PDGF-AB levels. c Decrease in PDGF-AB levels in different subgroups of PDGFA rs1800814. Individuals carrying the rs1800814 A allele (AA or GA) in both Acetazolamide and Ripc groups showed a significant decrease in PDGF-AB levels. Data are individual values, and mean with SD are showed

Back to article page